The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Over ten years since the game’s initial PC release, Facepunch Studios is releasing Rust Mobile. What’s even better is that, if you’re intrigued by this idea, you could be among the first to experience ...

You might think that explaining why the sky is blue would be kind of simple. But even a brief explanation of it requires a lot of science. The colors of everything you see are produced in different ...

Performances in N.Y.C. Advertisement Supported by Once used to frequent rejection letters, Blue has become a regular on major stages and is singing the title role in “Aida” at the Metropolitan ...

He probably felt alone for much of the night, too. Crosby’s favorite winger, the irreplaceable Bryan Rust, sustained a lower-body injury from a Radko Gudas hit in the second period and did not ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...